Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors
07 August 2013 - 10:00PM
Business Wire
Oral inhibitor of phosphorylated-p68 RNA
helicase marks Rexahn’s third oncology compound in clinical
development
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Rexahn Pharmaceuticals, Inc. (American Stock Exchange): 0 recent articles
More Rexahn Pharmaceuticals, Inc. News Articles